Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?

Figures & data

Table 1 Main Real-World Positive Therapeutic Effects of Biological Drugs in Patients with Severe Asthma

Real-World Study	Biological Drug	Main Results
Su N et al^Citation24	Omalizumab	↑ AQLQ, ↓ Exacerbations, ↑ FEV1
Rojo-Tolosa S et al^Citation25	Omalizumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Menzella F et al^Citation26	Omalizumab	↑ AQLQ, ↓ Exacerbations, ↑ FEV1
Menzella F et al^Citation27	Omalizumab	↑ AQLQ, ↑ ACT, ↓ Exacerbations, ↓ OCS
Campisi R et al^Citation28	Omalizumab	↑ ACT, ↓ Exacerbations, ↑ FEV1
Pilette C et al^Citation29	Mepolizumab	↓ ACQ-5, ↓ Exacerbations, ↓ OCS, ↓ WPAI
Pavord I et al^Citation30	Mepolizumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Rojo-Tolosa S et al^Citation31	Mepolizumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Korn S et al^Citation32	Mepolizumab	↓ Exacerbations, ↓ OCS
González-Pérez R et al^Citation33	Mepolizumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Jackson DJ et al^Citation34	Benralizumab	↑ AQLQ, ↓ ACQ-6, ↓ Exacerbations, ↓ OCS
Di Bona D et al^Citation35	Benralizumab	↑ AQLQ, ↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Martínez-Moragón E et al^Citation36	Benralizumab	↑ AQLQ, ↑ ACT, ↓ Exacerbations, ↓ OCS
Vultaggio A et al^Citation37	Benralizumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Scioscia G et al^Citation38	Benralizumab	↑ AQLQ, ↑ ACT, ↓ OCS, ↑ FEV1
Dupin C et al^Citation39	Dupilumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Campisi R et al^Citation40	Dupilumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Fukunaga K et al^Citation41	Dupilumab	↓ Exacerbations, ↓ OCS
Pelaia C et al^Citation42	Dupilumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1
Pelaia C et al^Citation43	Dupilumab	↑ ACT, ↓ Exacerbations, ↓ OCS, ↑ FEV1

Abbreviations: AQLQ, asthma quality of life questionnaire; FEV₁, forced expiratory volume in one second; ACT; asthma control test; OCS, oral corticosteroid; ACQ, asthma control questionnaire; WPAI, work productivity and activity impairment.

Figure 1 Real-world treatment effectiveness of biological therapies for severe type 2 asthma contribute to improve quality of life of patients. Omalizumab, mepolizumab, benralizumab, and dupilumab are able to reduce exacerbations and daily oral corticosteroid (OCS) intake, ameliorating lung function and asthma control test (ACT) score. These positive effects translate into notable improvements in terms of quality of life. Created with BioRender.com.

Su N, Zhi L, Liu F, et al. Real-world safety and effectiveness of omalizumab in moderate to severe allergic asthma patients in china: a post-authorization study. J Asthma Allergy. 2023;16:625–636. doi:10.2147/JAA.S406628

 PubMed Web of Science ®Google Scholar

Rojo-Tolosa S, González-Gutiérrez MV, Sánchez-Martínez JA, et al. Impact of omalizumab in patients with severe uncontrolled asthma and possible predictive biomarkers of response: a real-life study. Pharmaceutics. 2023;15(2):523. doi:10.3390/pharmaceutics15020523

 PubMed Web of Science ®Google Scholar

Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. doi:10.4168/aair.2017.9.4.368

 PubMed Web of Science ®Google Scholar

Menzella F, Fontana M, Contoli M, et al. Efficacy and safety of omalizumab treatment over a 16-year follow-up: when a clinical trial meets real-life. J Asthma Allergy. 2022;15:505–515. doi:10.2147/JAA.S363398

 PubMed Web of Science ®Google Scholar

Campisi R, Crimi C, Intravaia R, et al. Adherence to omalizumab: a multicenter ”real-world” study. World Allergy Organ J. 2020;13(2):100103. doi:10.1016/j.waojou.2020.100103

 PubMed Web of Science ®Google Scholar

Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646–2656. doi:10.1016/j.jaip.2022.05.042

 PubMed Web of Science ®Google Scholar

Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162. doi:10.3389/fimmu.2023.1150162

 PubMed Web of Science ®Google Scholar

Rojo-Tolosa S, González-Gutiérrez MV, Jiménez-Gálvez G, et al. Impact of Anti-IL5 therapies on patients with severe uncontrolled asthma and possible predictive biomarkers of response: a real-life study. Int J Mol Sci. 2023;24(3):2011. doi:10.3390/ijms24032011

 PubMed Web of Science ®Google Scholar

Korn S, Milger K, Skowasch D, et al. Real-world experience on the use of mepolizumab from the severe asthma registry of the German asthma net (MepoGAN-Study). J Asthma Allergy. 2023;16:541–552. doi:10.2147/JAA.S403286

 PubMed Web of Science ®Google Scholar

González-Pérez R, Poza-Guedes P, Mederos-Luis E, Sánchez-Machín I. Real-life performance of mepolizumab in T2-high severe refractory asthma with the overlapping eosinophilic-allergic phenotype. Biomedicines. 2022;10(10):2635. doi:10.3390/biomedicines10102635

 PubMed Web of Science ®Google Scholar

Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunol Pract. 2022;10(6):1534–1544.e4. doi:10.1016/j.jaip.2022.02.014

 PubMed Web of Science ®Google Scholar

Di Bona D, Minenna E, Albanesi M, Nettis E, Caiaffa MF, Macchia L. Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: data from a real-life cohort. Pulm Pharmacol Ther. 2020;64:101974. doi:10.1016/j.pupt.2020.101974

 PubMed Web of Science ®Google Scholar

Martínez-Moragón E, García-Moguel I, Nuevo J, Resler G. ORBE study investigators. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulm Med. 2021;21(1):417. doi:10.1186/s12890-021-01785-z

 PubMed Web of Science ®Google Scholar

Vultaggio A, Aliani M, Altieri E, et al. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023;24(1):135. doi:10.1186/s12931-023-02439-w

 PubMed Web of Science ®Google Scholar

Scioscia G, Carpagnano GE, Quarato CMI, et al. Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: our real-life experience. Front Pharmacol. 2021;12:631660. doi:10.3389/fphar.2021.631660

 PubMed Web of Science ®Google Scholar

Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.13614

 PubMed Web of Science ®Google Scholar

Campisi R, Crimi C, Nolasco S, et al. Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy. 2021;14:575–583. doi:10.2147/JAA.S312123

 PubMed Web of Science ®Google Scholar

Fukunaga K, Tagaya E, Ishida M, Sunaga Y, Koshiba R, Yokoyama A. Real-world impact of dupilumab on asthma disease burden in Japan: the CROSSROAD study. Allergol Int. 2023;72(4):537–544. doi:10.1016/j.alit.2023.04.001

 PubMed Web of Science ®Google Scholar

Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021;14:1165–1172. doi:10.2147/JAA.S328988

 PubMed Web of Science ®Google Scholar

Pelaia C, Benfante A, Busceti MT, et al. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. Front Immunol. 2023;14:1121237. doi:10.3389/fimmu.2023.1121237

 PubMed Web of Science ®Google Scholar